Resmed’s high margin and recurrent-revenue segment are the core attractions of its business. On margins, the outlook is positive Resmed’s improved update on sales costs and a proposed reduction in headcount. The impact of GLP-1 drugs on the sleep disorder device industry are overly pessimistic, but could deliver continued short term pain as the market factor in their impacts.
Resmed’s high margin and recurrent-revenue segment are the core...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$31.90 |
Change
0.120(0.38%) |
Mkt cap ! $20.20B | |||
| Open | High | Low | Value | Volume |
| $31.78 | $31.91 | $31.72 | $4.198M | 131.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 631 | $31.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $31.92 | 2031 | 6 |
View Market Depth
| Last trade - 11.11am 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$31.88 |
Change
0.120 ( 0.48 %) |
||||
| Open | High | Low | Volume | ||
| $31.77 | $31.92 | $31.72 | 23620 | ||
| Last updated 11.30am 07/06/2024 ? | |||||
| RMD (ASX) Chart |